Excitement is building around a new weight loss drug, CagriSema, which is expected to surpass the effects of popular drugs ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO), the kings of the titanic weight-loss drugs market, might have a problem on their hands. After reporting their third-quarter earnings, shares of both ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today ...

A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...

The latest celebrity weight-loss drug to be given the nod in Hong Kong will be available in December, but experts cautioned ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the ...

Pharmaceutical executives and public health experts have warned that Robert F Kennedy jnr’s influence over Donald Trump could ...

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

That may leave some Americans to question whether they'll find their local stores, banks, post offices, DMV and other services open on November 5. At the same time, some schools are closed on Election ...

Novo Nordisk is paying $55 million upfront to secure ... In this issue, we unpack Ozempic’s rise to superstar status and the risks associated with its off-label use. The launch environment ...